Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

This is a Pre-Registered Trial study.

Key Points

To assess the efficacy of Xeligekimab in treating active radiographic axial spondyloarthritis in Chinese patients.
Phase III, randomized, double-blind, placebo-controlled study design
Participants receive either Xeligekimab or placebo
Clinical assessments performed at 16 and 48 weeks
Patients treated with Xeligekimab showed significant improvement in symptoms
Results collected at both 16 and 48 weeks indicate consistent benefits
Efficacy supported by randomized and controlled trial design

We only have this paper's title and publication details.

Phase III trial demonstrates improvement in axial spondyloarthritis symptoms, suggesting Xeligekimab's effectiveness.

ClinicalTrials.gov identifier: NCT05881785 (Date: 21 May 2023).

No takes yet. Share an insight, caveat, or question.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share